Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from SSY Group ( (HK:2005) ).
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new drugs: Acetylcysteine Injection and Compound Sodium Acetate Ringer’s Injection. These approvals mark significant progress in the company’s product development, enhancing its position in the pharmaceutical market by expanding its portfolio of approved medical solutions.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating medical solutions primarily for detoxification and fluid supplementation, with a market focus on China.
Average Trading Volume: 9,820,517
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.94B
For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.